Search results

Medical Sales Representative CANDIDATES MUST BE BASED IN NEW YORK STATE OR NORTHERN NEW JERSEY AND MUST HAVE EXPERIENCE WORKING IN SALES TO MEDICAL PRACTICES OR SURGERY CENTERS IN ANY OF THE BELOW LISTED SPECIALTIES IN NEW YORK STATE AND/OR NEW JERSEY WITH A BOOK OF CONTACTS. CANDIDATES NOT...

Medical Sales Representative CANDIDATES MUST BE BASED IN NEW YORK STATE OR NORTHERN NEW JERSEY AND MUST HAVE EXPERIENCE WORKING IN SALES TO MEDICAL PRACTICES OR SURGERY CENTERS IN ANY OF THE BELOW LISTED SPECIALTIES IN NEW YORK STATE AND/OR NEW JERSEY WITH A BOOK OF CONTACTS. CANDIDATES NOT...

via TNKase is the first stroke drug to win FDA approval in nearly three decades. The FDA signed off Monday on the use of Roche’s thrombolytic drug TNKase to treat acute ischemic stroke in adult patients. According to Roche subsidiary Genentech, which announced the label expansion on Monday...

via China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina, just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect. article source

via A year after the FDA blessed Roche and Novartis’ Xolair (omalizumab) as the first medicine to reduce allergic reactions that can occur from accidental exposure to certain foods, the companies have presented data indicating Xolair may be more effective than oral immunotherapy (OIT) in...

via Trelegy Ellipta and Breo Ellipta, two drugs selected to be part of the next set of drugs to be assessed under Medicare’s drug price negotiation program, offer the advantage of requiring only one puff once a day compared with other therapies to treat chronic obstructive pulmonary disease...

via The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the drug in gastric and gastroesophageal cancers as BeiGene also pushes forward a pipeline of novel cancer therapies. article source

via Bayer's CEO is facing increasing investor pressure to deliver on turnaround efforts and reverse a forecast earnings decline this year, as the group prepares to release quarterly results on Wednesday. article source

via Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful ‘improvement’ in the DESTINY-Gastric04 Phase III trial, regarding the primary endpoint of overall survival (OS) in individuals with gastric or gastroesophageal junction (GEJ) adenocarcinoma...

via The social media landscape is shifting. As X becomes a battleground for increasingly polarised debate, its lesser-known (but strikingly similar) cousin is rapidly gaining traction. article source

via Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options. article source

via Pfizer (PFE) CEO Albert Bourla said on Monday that the drugmaker could move some of its overseas manufacturing to its U.S. plants if necessary, as the Trump administration considers imposing tariffs on pharmaceuticals. article source

via 23andMe’s special committee of independent directors on Monday rejected CEO Anne Wojcicki’s proposal to take the distressed genetic testing company private. Wojcicki submitted a proposal to the committee on Sunday, offering to acquire all of the company’s outstanding shares for 41 cents...

via Atara Biotherapeutics is halving its head count as it navigates the fallout from the FDA’s move to halt trials of the allogeneic T-cell immunotherapy Ebvallo and a CAR-T candidate. article source

via Sanofi is paying Biond Biologics $125 million upfront for global rights to a novel immune checkpoint inhibitor. The agreement gives Sanofi a near-clinical anti-ILT2 monoclonal antibody designed to turn the innate and adaptive immune systems against tumors. article source

via Callio Therapeutics is debuting with an ADC technology and related programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience. article source

via Biohaven Pharmaceuticals' Kv7.2/7.3 potassium channel activator BHV-7000 failed to meet the primary endpoint in a Phase III bipolar mania trial. The three-week study "did not statistically separate from the comparator" on the Young Mania Rating Scale primary outcome measure, the company said...

via The company has chosen to move ahead to Phase III trials with its 10mg dose after it saw a 1.74-point reduction in pain score. article source

via AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.87 billion in milestones, has landed the drugmaker rights to a long-acting amylin analog that is in phase 1 development at Gubra. article source

via Novo Nordisk has forged a deal with Gensaic, agreeing to pay up to $354 million per target to access technology for the tissue-selective delivery of molecules to cardiometabolic targets inside cells. article source